In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free ...

Global Bispecific Trispecific Antibodies Market Size Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, April 04, ...

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...

The global CD Antigen Cancer Therapy Market is valued at USD 27.5 Billion in 2024 and is projected to reach a value of USD 54 ...

An In-depth Market Research ReportThe Cancer Biologics Market is one of the fastest-growing segments within the global ...

Biocon Biologics, the biosimilar arm of Biocon has expanded its oncology portfolio with the USFDA approval of Jobevne, a ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030 Report" report has been added to ResearchAndMarkets.com's offering.Global LAG-3 Targeting Therapy Market, Drug ...